This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Evaluate Safety, Efficacy and Pharmacokinetics (Compare)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Celltrion Identifier:
First received: March 5, 2010
Last updated: February 11, 2015
Last verified: February 2015
The purpose of the study is to demonstrate equivalent pharmacokinetics (PK)

Condition Intervention Phase
Metastatic Breast Cancer Drug: CT-P6 Drug: Herceptin Drug: Paclitaxel Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Double-blind Randomised Phase I/IIb Study

Resource links provided by NLM:

Further study details as provided by Celltrion:

Primary Outcome Measures:
  • PK parameter [ Time Frame: months ]

Secondary Outcome Measures:
  • PK data, safety and efficacy [ Time Frame: months ]

Enrollment: 174
Study Start Date: January 2010
Estimated Study Completion Date: December 2017
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: CT-P6 & Paclitaxel
CT-P6 + Paclitaxel
Drug: CT-P6
CT-P6: administered every 3 weeks
Drug: Paclitaxel
Paclitaxel: administered every 3 weeks
Active Comparator: Herceptin & Paclitaxel
Trastuzumab + Paclitaxel
Drug: Herceptin
Herceptin: administered every 3 weeks
Other Name: Trastuzumab
Drug: Paclitaxel
Paclitaxel: administered every 3 weeks

Detailed Description:
Patients will receive CT-P6 or Herceptin.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Are females
  • Have a Her 2 over-expression
  • Have ECOG 0 or 1

Exclusion Criteria:

  • Current clinical or radiographic evidence CNS metastases
  • Current Known infection
  • Pregnant or nursing mother
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01084863

Korea, Republic of
Samsung Medical Center
Seoul, Korea, Republic of
Sponsors and Collaborators
Principal Investigator: Investigational Site Samsung Medical Center
  More Information

Responsible Party: Celltrion Identifier: NCT01084863     History of Changes
Other Study ID Numbers: CT-P6/1.1
Study First Received: March 5, 2010
Last Updated: February 11, 2015

Keywords provided by Celltrion:
Her 2-positive
metastatic breast cancer

Additional relevant MeSH terms:
Albumin-Bound Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action processed this record on September 21, 2017